Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 205 of the 222 references it cites were found in a registry or an index; 39 of the 219 sources its claims cite were checked for support.

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

Open access

Abstract

OBJECTIVE: This clinical practice guideline addresses the diagnosis and treatment of primary adrenal insufficiency. PARTICIPANTS: The Task Force included a chair, selected by The Clinical Guidelines Subcommittee of the Endocrine Society, eight additional clinicians experienced with the disease, a methodologist, and a medical writer. The co-sponsoring associations (European Society of Endocrinology and the American Association for Clinical Chemistry) had participating members. The Task Force received no corporate funding or remuneration in connection with this review. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to determine the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: The evidence used to formulate recommendations was derived from two commissioned systematic reviews as well as other published systematic reviews and studies identified by the Task Force. The guideline was reviewed and approved sequentially by the Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee, members responding to a web posting, and the Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. CONCLUSIONS: We recommend diagnostic tests for the exclusion of primary adrenal insufficiency in all patients with indicative clinical symptoms or signs. In particular, we suggest a low diagnostic (and therapeutic) threshold in acutely ill patients, as well as in patients with predisposing factors. This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension. We recommend a short corticotropin test (250 μg) as the "gold standard" diagnostic tool to establish the diagnosis. If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels. Diagnosis of the underlying cause should include a validated assay of autoantibodies against 21-hydroxylase. In autoantibody-negative individuals, other causes should be sought. We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15-25 mg/d) or cortisone acetate replacement (20-35 mg/d) applied in two to three daily doses in adults. In children, hydrocortisone (∼8 mg/m(2)/d) is recommended. Patients should be educated about stress dosing and equipped with a steroid card and glucocorticoid preparation for parenteral emergency administration. Follow-up should aim at monitoring appropriate dosing of corticosteroids and associated autoimmune diseases, particularly autoimmune thyroid disease.

Overview

CoChat Summary

TL;DR

This Endocrine Society clinical practice guideline provides evidence-based recommendations for diagnosing and treating primary adrenal insufficiency (PAI), emphasizing a low diagnostic threshold, the 250-µg short corticotropin test as the diagnostic gold standard, and glucocorticoid/mineralocorticoid replacement with adrenal crisis prevention. It also highlights major evidence gaps, including sparse randomized trial data for replacement regimens and limited diagnostic accuracy studies specifically in PAI.

Key findings

  • For diagnosis, the guideline recommends testing patients with indicative symptoms/signs and using the standard-dose 250-µg corticotropin stimulation test as the “gold standard”; peak cortisol below 500 nmol/L (18 µg/dL) at 30 or 60 minutes indicates adrenal insufficiency. The high-dose ACTH stimulation test had a sensitivity of 92% (95% CI, 81–97%) for PAI based on five studies; no studies were available for the low-dose test in PAI. If corticotropin testing is not feasible, a morning cortisol <140 nmol/L (5 µg/dL) plus ACTH is suggested as a preliminary test.
  • Autoimmune adrenalitis is the most common cause of PAI, accounting for up to 90% in Western countries; 21-hydroxylase autoantibodies should be measured, and about 30% of CYP21A2 autoantibody-positive individuals progressed to overt PAI during 5-year follow-up. In autoantibody-negative individuals, other causes should be sought, including adrenoleukodystrophy in males via very-long-chain fatty acids and adrenal CT for infiltrative or malignant disease.
  • In adults, recommended replacement is hydrocortisone 15–25 mg/d or cortisone acetate 20–35 mg/d in two or three divided doses, with fludrocortisone starting at 50–100 µg/d (median, 0.1 mg) for confirmed aldosterone deficiency. Prednisolone 3–5 mg/d is an alternative, while dexamethasone is suggested against. DHEA replacement may be tried for 6 months in women with low libido, depressive symptoms, and/or low energy despite optimized replacement.
  • For adrenal crisis, immediate parenteral hydrocortisone 100 mg (50 mg/m² for children) is recommended, followed by 200 mg/24 h (50–100 mg/m²/d for children), plus fluid resuscitation. Reported adrenal crisis frequencies were 6.6 crises/100 patient-years in a retrospective analysis of 444 patients and 8.3 crises/100 patient-years in a prospective study of 768 patient-years, with a crisis mortality rate of 0.5/100 patient-years.

Methods

  • This is a GRADE-based clinical practice guideline developed by an Endocrine Society Task Force with a methodologist and medical writer; recommendations are graded strong (“we recommend,” 1) or weak (“we suggest,” 2), with evidence quality from QEEE (very low) to QQQQ (high), plus ungraded best practice statements.
  • Evidence came from two commissioned systematic reviews and other published systematic reviews/studies. The first review compared high-dose vs low-dose ACTH stimulation for diagnosis and found only five studies for high-dose ACTH in PAI and none for low-dose ACTH in PAI. The second review compared glucocorticoid replacement regimens and identified 15 observational studies; mortality, bone density, and adrenal crisis data were very sparse or unavailable, and there was no statistically significant HRQoL difference between hydrocortisone dosages ≥30 mg/d vs <30 mg/d.
  • The guideline was reviewed and approved sequentially by Endocrine Society committees, members responding to a web posting, and the Endocrine Society Council; the Task Force received no corporate funding or remuneration.

Limitations

  • The paper states that the evidence base is limited: there are no randomized controlled trials for many treatment questions, diagnostic accuracy data for high-dose ACTH in PAI come from only five studies with none for low-dose ACTH in PAI, and the second systematic review found sparse or unavailable data on mortality, bone density, and adrenal crisis, with very low-quality evidence for extended-release/dual-release glucocorticoids. Many recommendations are weak or ungraded best practice statements.
  • The paper states that cortisol cutoff values after corticotropin stimulation vary by assay, ACTH assays have analytical bias, and actual clinical cutpoints should be based on assay-specific normative data.
  • Evident from the text: the guideline focuses only on PAI and explicitly excludes secondary adrenal insufficiency and critical illness-related corticosteroid insufficiency; some recommendations rely on clinical experience, unsystematic observations, and values/preferences rather than direct systematic evidence.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/jc.2015-1710

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Algorithm for the diagnostic approach to the patient with PAI. The most common causes of PAI are autoimmune destruction of the adrenal cortex in adults and CAH in children. These etiologies can be screened for using 21-hydroxylase antibodies and a baseline serum 17hydroxyprogesterone level. Males with negative 21-hydroxylase antibodies should be tested for adrenoleukodystrophy with plasma VLCFAs. If these diagnoses are excluded, a CT scan of the adrenals may reveal evidence of adrenal infiltrative processes or metastases. The individual's clinical picture and family history may render some steps in the algorithm redundant or suggest specific genetic syndromes. The latter includes subtypes of autoimmune polyglandular syndromes or specific rare genetic disorders where adrenal failure is part of a broader phenotype. A list of differential diagnoses is provided in Table 2. AHC, adrenal hypoplasia congenita; AI, adrenal insufficiency; VLCFA, very long chain fatty acid. a 17-OHprogesterone > 1000 ng/dL is diagnostic for 21-OH deficiency (14). b VLCFA should be measured in the initial evaluation of preadolescent boys. [Adapted from E. S. Husebye, et al: Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med . 2014;275:104-115 (181), with permission. © John Wiley & Sons, Inc.]
Figure 1 Algorithm for the diagnostic approach to the patient with PAI. The most common causes of PAI are autoimmune destruction of the adrenal cortex in adults and CAH in children. These etiologies can be screened for using 21-hydroxylase antibodies and a baseline serum 17hydroxyprogesterone level. Males with negative 21-hydroxylase antibodies should be tested for adrenoleukodystrophy with plasma VLCFAs. If these diagnoses are excluded, a CT scan of the adrenals may reveal evidence of adrenal infiltrative processes or metastases. The individual's clinical picture and family history may render some steps in the algorithm redundant or suggest specific genetic syndromes. The latter includes subtypes of autoimmune polyglandular syndromes or specific rare genetic disorders where adrenal failure is part of a broader phenotype. A list of differential diagnoses is provided in Table 2. AHC, adrenal hypoplasia congenita; AI, adrenal insufficiency; VLCFA, very long chain fatty acid. a 17-OHprogesterone > 1000 ng/dL is diagnostic for 21-OH deficiency (14). b VLCFA should be measured in the initial evaluation of preadolescent boys. [Adapted from E. S. Husebye, et al: Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med . 2014;275:104-115 (181), with permission. © John Wiley & Sons, Inc.]From the PDF

Verification

Claims the paper makes

35 Valid · 2 Not valid · 109 Not checked · 48 Own results and interpretations

118 more claims · 24 with their cited sources checked

Create a free account to see all 194 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 58
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

25 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 222 references

Research works printed but not linked: 3

  1. [29]29. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insuffi- ciency. Ann Intern Med. 2003;139:194 -204.
  2. [110]110. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on miner- alocorticoid replacement with fludrocortisone in adrenal insuffi- ciency. Am J Med Sci. 1986;291:280 -283.
  3. [177]177. Gan EH, MacArthur K, Mitchell AL, et al. Residual adrenal func- tion in autoimmune Addison's disease: improvement after tetra- cosactide (ACTH1-24) treatment. J Clin Endocrinol Metab. 2014; 99:111-118.

Cited by

See all 1,769

Metadata

Authors
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., & Torpy, D. J.
Affiliations
  • King's College London (GB)
  • Mayo Clinic (US)
  • National Institutes of Health (US)
  • Royal Adelaide Hospital (AU)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2016-02
Volume
101
Issue
2
Pages
364-389
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2234917292
Cited by
1,769
References
222
Citations by year
2026: 187 · 2025: 198 · 2024: 180 · 2023: 191 · 2022: 180 · 2021: 206 · 2020: 165 · 2019: 149 · 2018: 148 · 2017: 102 · 2016: 54
FWCI
151.55
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, cc-by-nc-nd)
  • Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by-nc-nd)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • European Society of Endocrinology
  • Novo Nordisk Fonden (NNF14OC0011005)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK062027)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
Addison's disease, diagnosis, hydrocortisone replacement, fludrocortisone, corticosteroid dose, stress dosing, 21-hydroxylase autoantibodies, autoimmune thyroid disease, pregnancy, glucocorticoid therapy, autoimmune adrenal insufficiency
MeSH terms
Adrenal Insufficiency, Female, Humans, Pregnancy, Societies, Medical, Evidence-Based Medicine, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. https://app.cochat.ai/papers/10.1210/jc.2015-1710
The paper
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., & Torpy, D. J. (2016). Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-1710

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.